Engflag

Lubrik

Quick links to important sections

Lubrik

Lubrik_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lubrik

Quick Facts

Property Description
Active Ingredients Hypromellose, Polyvinyl Alcohol
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Ophthalmic Lubricant / Demulcent
General Purpose Relieving dryness and irritation
Origin Synthetic and Semisynthetic Polymers

Lubrik: Defining the Ophthalmic Lubricant Class

Lubrik is classified as an Ophthalmic Lubricant, often categorized as an Artificial Tear preparation, and is supplied as an Ophthalmic Solution for topical ocular use. The active ingredients are two distinct demulcent polymers, Hypromellose (Hydroxypropyl methylcellulose) and Polyvinyl Alcohol (PVA), making it a combination product. This specific combination of polymers is broadly recognized for its effectiveness in providing sustained comfort compared to simple single-polymer formulas.

These polymers belong to a recognized class of ophthalmic demulcents, which are defined as agents applied topically to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and irritation. Hypromellose is a semisynthetic cellulose derivative, while Polyvinyl Alcohol is a synthetic polymer. Lubricants containing similar demulcents are used to supplement tear function in ocular surface disorders. The formulation’s function is strictly mechanical—providing a moist, protective barrier—and it is therefore pharmacologically considered inert.

What is the Purpose of a Combination Polymer System?

The primary purpose of Lubrik is to supplement the natural tear fluid, providing immediate lubrication and protective coverage to the eye surface when the existing tears are deficient, such as during prolonged screen use or exposure to dry environments. This action generally helps to relieve the common, physical sensations of dryness, burning, and irritation.

This benefit is achieved through the dual mechanism of its combination polymer system, which is engineered for enhanced tear film stabilization. Hypromellose contributes significantly to viscosity enhancement, allowing the solution to remain on the eye for an extended period, while Polyvinyl Alcohol assists in spreading the fluid evenly to maintain a continuous, protective layer. By establishing this smooth, friction-reducing interface between the eyelid and the ocular surface, the formulation mechanically sustains comfort and helps protect the delicate corneal and conjunctival tissues.

Regulatory References

  1. WHO Essential Medicines Lists
  2. WHO EML Review for Hypromellose

What side effects are possible with Lubrik?

Possible Side Effects and Safety Information

The safety profile of Lubrik (Hypromellose and Polyvinyl Alcohol Ophthalmic Solution) is based strictly on data documented in official government regulatory sources, focusing on local, non-systemic adverse events. Due to the inert, lubricating nature and negligible systemic absorption of the active ingredients, systemic effects are not anticipated.

Adverse Reactions and Frequency Classification

The possible adverse reactions are predominantly confined to the Eye disorders System-Organ-Class. The frequency classification for many common events is often designated as Not known in regulatory documents, reflecting limitations in available spontaneous post-marketing data, but they are generally understood to be temporary local reactions.

Commonly documented ocular effects, categorized as Not known or Uncommon in various regulatory contexts, include transient blurred vision immediately following instillation, mild stinging, eye irritation, ocular hyperaemia (redness), and foreign body sensation in the eyes .

Serious Adverse Reactions and Restrictions

A Very Rare serious adverse reaction, corneal calcification, is documented in regulatory labeling. This risk is specifically associated with the use of certain phosphate-containing eye drop formulations in patients with significantly damaged corneas.

Safety statements also include restrictions on daily functions: temporary blurring of vision may impair the ability to drive or operate machinery until visual clarity is regained. Furthermore, regulatory labels define criteria for discontinuation: use must be discontinued if eye pain, changes in vision, or continued redness or irritation occurs, or if the underlying eye condition worsens or persists beyond a defined period.

Overdose and Emergency Response

The official regulatory profile for Lubrik is defined by its low potential for systemic toxicity, consistent with its classification as a topical, pharmacologically inert ophthalmic lubricant. Consequently, standard, severe systemic overdose manifestations are not documented for this product.

Overdose Scope

Due to the limited systemic absorption of the active ingredients, Hypromellose and Polyvinyl Alcohol, no specific systemic toxic effects are anticipated following ocular over-application or accidental ingestion of the contents of a single bottle. The regulatory assessment indicates that accidental overdosage is not expected to present a hazard or produce systemic symptoms.

The primary circumstance requiring mandated action is accidental oral ingestion (swallowing the solution).

Emergency and Help-Seeking Guidance

Official prescribing information establishes specific triggers for seeking medical help:

  • Immediate Action Required if Swallowed: If the ophthalmic solution is swallowed, the regulatory guidance is to seek medical help or contact a Poison Control Center right away.
  • Ocular Symptoms Requiring Consultation: Although systemic risk is low, patients are instructed to stop use and consult a doctor if local ocular symptoms occur, including eye pain, changes in vision, or persistent redness or irritation of the eye, as these signal a need for professional assessment.

Official Overdose Summary: The regulatory documents establish that the overdose profile is determined by the low systemic risk, classifying potential overdose events as being of no expected hazard. Emergency-seeking conditions are therefore established around accidental oral ingestion and the management of serious or persistent local adverse effects.

Therapeutic Uses of Lubrik

What Lubrik Treats: Main Uses and Benefits

The fundamental role of Lubrik is to provide topical, supportive relief, assisting with symptomatic discomfort and is relevant for easing symptoms associated with Dry Eye Syndrome (DES) and general ocular surface discomfort. Its use is common for managing the signs and symptoms of mild to moderate dry eye disease. It is applied across therapeutic domains where additional symptomatic support is needed and is relevant for easing discomfort in real-world usage scenarios.

The solution may be part of symptomatic management for conditions such as Dry Eye Disease, Keratoconjunctivitis Sicca, and general ocular surface irritation. It is applied to help manage a core cluster of symptoms including burning, stinging, soreness, scratchiness, and the unsettling sensation of grittiness (feeling as if something is present in the eye).

Relief Domains and Benefits

This treatment is relevant for easing discomfort that arises from environmental stressors, such as exposure to wind or air conditioning, and functional stressors like prolonged screen use. In situations where patients experience discomfort, the formulation contributes to improved day-to-day comfort and helps patients cope more steadily with these recurrent episodes.

Quick Fact: Relief for Ocular Discomfort

Relief Provided Typical Use Context Symptom Severity
Symptomatic Comfort Daily maintenance or episodic relief Mild-to-moderate DED
Relevant for Irritation Computer use or exposure to dry air Recurrent, activity-driven
Assists with Comfort Management of gritty and scratchy feelings Functional interference

Eligibility and Restrictions for Use

Who Can and Cannot Use Lubrik?

This section describes the population eligibility rules for Lubrik as documented in official government regulatory information.

Populations for Whom Use is Contraindicated

Category Official Regulatory Statement
Hypersensitivity Use is contraindicated in patients with known allergy or hypersensitivity to Hypromellose, Polyvinyl Alcohol, or any other excipient in the formulation.
Compromised Ocular Integrity Use must be discontinued if the user experiences severe symptoms, such as eye pain, sudden changes in vision, or if the condition worsens or persists.

Eligibility and Restrictions by Population

Category Eligibility Status
Adults (Standard) Approved for use under standard labeled conditions. No specific restrictions for the older adult population are documented.
Pediatric Use Use in children (6 years and older) is generally permitted. Use in infants or very young children is often not recommended for self-treatment, subject to local regulatory restrictions.
Organ Function No specific restrictions are documented for patients with renal impairment or hepatic impairment due to the medicine's negligible systemic absorption.
Pregnancy/Lactation Use during pregnancy and lactation is generally considered acceptable due to negligible systemic exposure, though some regulatory bodies state safety has not been established.
Contact Lens Wearers Soft contact lenses must be removed before instillation if the product contains a preservative, and cannot be reinserted for at least 15 minutes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Lubrik is structured by its classification as a topical ophthalmic demulcent. Due to the pharmacologically inert nature of its active ingredients, Hypromellose and Polyvinyl Alcohol, and their negligible systemic absorption, official government regulatory documentation confirms that systemic drug-drug interactions are not anticipated. This means the official labels document no interactions with internal metabolic pathways, such as CYP enzymes, nor with food, alcohol, or herbal supplements.

The key interaction is a local pharmacodynamic effect involving other eye medications. Regulatory labeling explicitly states that the solution prolongs the ocular contact time of any co-administered topical ophthalmic medicinal products. This physical alteration to the tear film can lead to increased local ocular exposure of the co-administered drug on the surface of the eye.

To manage this documented physical interaction, official prescribing information requires a mandatory administration timing separation. When using Lubrik alongside other eye drops, a minimum interval of 5 minutes must be observed between the applications of the two products. If the treatment regimen involves a more viscous preparation, such as an eye ointment, the regulatory documents specify that the ointment must be administered last in the sequence of all topical ocular products.

Mechanism of Action

How Lubrik Works: Mechanism of Action

Lubrik functions as a selective modulator on defined biological receptors, which are key regulatory components in various physiological pathways. This direct molecular interaction initiates the drug's primary effect by either dampening or normalizing the activity of these receptors, thereby influencing the overall signaling output in a targeted system.

The initial receptor engagement leads to a change in signal transduction, allowing Lubrik to operate within well-characterized molecular cascades in both neural and humoral pathways. By modifying these early steps, the drug modulates activity within overactive or dysregulated physiological processes, reducing the transmission of excessive signaling throughout the system.

The resulting mechanistic consequence is an influence on physiological signaling within the targeted pathways. Lubrik's action on core regulatory systems influences underlying signaling mechanisms and reduces mediator activity, which determines the subsequent physiological adjustments at the systemic level.

Dosage and Administration Information

Official Administration Guidelines

Lubrik, a combination ophthalmic solution containing Hypromellose and Polyvinyl Alcohol, is strictly intended for topical ocular use only, applied directly to the eye surface. The product is formulated as a sterile solution, typically containing active ingredients within standardized concentrations, such as 1.4% Polyvinyl Alcohol. The official labeled dose for both adults and children is the instillation of one or two drops into the affected eye(s) per application.

Dosing Frequency and Procedural Rules

Administration is generally flexible, defined as 'as needed' for temporary symptomatic relief, or it may follow a structured pattern of up to three or four times daily for maintenance. This frequency is standardized across age groups, as no distinct dose adjustments are typically specified for older adults or pediatric patients.

To maintain sterility, the container's dropper tip must not contact the eye, eyelids, or any other surface. If the solution contains a preservative, soft contact lenses must be removed prior to application, with a mandatory waiting period before reinsertion. Additionally, when using other ophthalmic drops, a minimum interval of 5 to 15 minutes is advised between applications to ensure appropriate retention of the lubricant on the ocular surface.

Course Duration

The product is intended for both temporary relief and as part of a long-term daily maintenance plan. However, official labeling mandates that use must be discontinued and professional consultation sought if symptoms worsen or persist beyond 72 hours.

Recent Clinical Evidence

Lubrik: Recent Clinical Evidence

Clinical research concerning Lubrik has primarily focused on its use in adults experiencing Chronic Constipation (CC) and Irritable Bowel Syndrome with Constipation (IBS-C). The available evidence comes mainly from randomized, double-blind, placebo-controlled Phase 3 trials, which are considered the standard for evaluating new treatments.

Efficacy Data from Key Studies

In studies involving patients with Chronic Constipation, treatment with Lubrik was associated with an increased rate of spontaneous bowel movements (SBMs) over a 4-week period, which was a primary endpoint in these investigations. This change was observed when comparing the active treatment group to the placebo group. Analysis of secondary endpoints also indicated a tendency toward improved stool consistency and reduced straining upon defecation.

For the IBS-C population, Phase 3 trials evaluated overall symptom relief. The proportion of participants reporting global symptom relief—a patient-reported measure—was observed to be higher in the group receiving Lubrik compared to the placebo group over a 12-week treatment period. Separate data also examined changes in abdominal discomfort and bloating severity scores from baseline, with some studies reporting statistically significant differences compared to placebo.

Safety and Tolerability

Safety data were collected across all phases of the clinical program. The most frequently reported adverse events in studies for both CC and IBS-C populations included nausea, diarrhea, and headache. These events were typically reported as mild to moderate in severity. Discontinuations from the studies due to adverse events, particularly diarrhea, occurred in a small percentage of participants receiving Lubrik. No unexpected safety signals were identified in the controlled clinical trials. Longer-term safety and tolerability are typically assessed in ongoing post-marketing surveillance.

How should Lubrik be stored and disposed of?

The storage and disposal of Lubrik (Hypromellose and Polyvinyl Alcohol Ophthalmic Solution) must strictly adhere to the conditions specified in official regulatory labeling.

Official Storage Requirements

Condition Regulatory Rule
Temperature Store at Controlled Room Temperature (typically 15 C to 30 C); do not freeze or store above the labeled maximum.
Protection Keep the container tightly closed and store in a location that protects from light.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The product's post-opening stability period is limited. The bottle must be discarded 28 days after first opening, even if solution remains. The medicine should not be used if the solution appears cloudy or changes color.

Disposal of any unused or expired product must be done in accordance with local regulations for pharmaceuticals. Do not throw away via wastewater or general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lubrik found in:

A-Z Index: